|
Protocol Number:
97-C-0077
- Title:
Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype
- Number:
97-C-0077
- Summary:
Patients undergo chemotherapy until remission is obtained, or disease has been stable for two cycles of chemotherapy, or progressive disease develops.
Three to six months after completion of chemotherapy, patients who have achieved complete clinical remission or minimal disease status receive a series of 5 injections (given 1-2 months apart) of a vaccine consisting of 0.5 mg autologous tumor-derived immunoglobulin (Id) conjugated to KLH. The vaccine is administered with subcutaneous QS-21 as an immunological adjuvant.
- Sponsoring Institute:
-
National Cancer Institute (NCI)
- Recruitment Detail
- Type:
No longer recruiting/follow-up only
- Gender:
Male & Female
- Referral Letter Required:
Yes
- Population Exclusion(s):
Children
- Eligibility Criteria:
This study is not currently recruiting new subjects. If you have questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
- Special Instructions:
Many protocols are potentially hazardous, are intended only for use by clinical oncologists in carefully structured settings, and may not prove to bemore effective than standard treatment. A responsible investigator associated with this protocol should be consulted before using this protocol. Dose and schedule modifications are required for patients who develop gastrointestinal, hematologic, neurologic, and biochemical (renal, hepatic, etc.) and/or other abnormalities after the administration of therapy. Additionally, Federal regulations for the protection of human subjects require approval of clinical trials by your local Institutional Review Board.
- Keyword(s):
-
B-Cell Lymphoma
-
BCL- 2 Positive Tumor
-
Immunization
-
Induction Chemotherapy
-
Lymphoma Vaccine
- Recruitment Keyword(s):
-
None
- Condition(s):
-
B Cell Lymphoma
-
Follicular Lymphoma
-
Neoplasm
- Investigational Drug(s):
-
Id-KLH Vaccine
- Investigational Device(s):
- None
- Interventions:
-
Drug: Id-KLH Vaccine
-
Drug: QS-21 (Stimulation-QS-21) Drug
- Supporting Site:
-
National Cancer Institute
- Contact(s):
-
This study is not currently recruiting new subjects. If you have questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
- Citation(s):
-
Antibody to molecularly defined antigen confined to a tumor cell surface
-
Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins
-
Induction of immune responses in patients with B cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors
If you have:
Search The Studies | Help | Questions | Clinical Center Home | NIH Home
National Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 01/17/2009
|
|